Dr Jeremy Braybrooke
Contact information
Jeremy Braybrooke
BSc, BM, FRCP, PhD
Senior Clinical Research Fellow
Jeremy is a Consultant Medical Oncologist and clinical lead for oncology at University Hospitals Bristol NHS Foundation Trust. He has worked in Bristol since 2003 and developed a large research focused clinical practice specialising in breast and testicular cancers.
Jeremy sits on a NICE Technology Appraisal Committee evaluating new medicines and is a member of the Royal College of Physicians Specialist Advisory Committee for medical oncology training. He is actively involved in clinical research and since 2016 has worked part time as a Senior Clinical Research Fellow within the Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
He trained in medical oncology at the Cancer Research UK Medical Oncology Unit in Oxford. During this time he completed a PhD in DNA damage and repair pathways.
Recent publications
The Mistletoe and Breast Cancer (MAB) Study: A UK Mixed-Phase, Pilot, Placebo-Controlled, Double-Blind, Randomised Controlled Trial.
Journal article
Duncan LJ. et al, (2025), Cancers (Basel), 17
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
Journal article
Abraham JE. et al, (2025), Nat Commun, 16
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Journal article
Abraham JE. et al, (2024), Nature, 629, 1142 - 1148
Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
Journal article
Braybrooke J. et al, (2024), Lancet, 403
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.
Journal article
Copson ER. et al, (2023), Breast, 72